Mode
Text Size
Log in / Sign up
N/A N=25 Randomized Single-blind Treatment

Neurofeedback-enhanced Mindfulness Meditation in Traumatic Brain Injury

Traumatic Brain Injury

Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcome: Primary: Change in Neurobehavioral Symptom Inventory — 35.2; 33.1; 27.7; 24.6 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
EEG neurofeedback-assisted meditation (Device); Non-EEG feedback-assisted meditation (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Spaulding Rehabilitation Hospital
Primary completion
Dec 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Neurobehavioral Symptom Inventory
35.2; 33.1; 27.7; 24.6
SECONDARY
Change in Wechsler Adult Intelligence Scale-IV Digit Span
10.4; 11.2; 10.9; 11.8
SECONDARY
Change in Wechsler Adult Intelligence Scale-IV Digit Symbol Coding
11.6; 11.1; 13.1; 12.5
SECONDARY
Change in Trail Making Test
10.9; 11.9; 12.3; 12.7
SECONDARY
Change in Beck Anxiety Inventory
15.9; 18.8; 11.5; 8.5
SECONDARY
Change in Beck Depression Inventory-II
19.9; 17; 13.1; 9.9
SECONDARY
Change in Cognitive and Affective Mindfulness Scale-Revised
24.2; 24.7; 27.3; 28.3
SECONDARY
Change in Percentage of EEG Activity Associated With Alpha, Beta, and Theta Rhythms as Measured by Surface Electrodes on the MUSE Device
49.7; 32; 57.7; 43.7

Summary

Spaulding Rehabilitation Hospital is conducting a research study evaluating the effectiveness of the brain-training product, MUSE, an EEG-guided neurofeedback device designed to assist in cultivating a relaxed, attentive state of mind during meditation. The investigators study aims to evaluate whether such a tool could be useful in treating persistent traumatic brain injury symptoms such as inattention, impulsivity, irritability, or dysregulated mood.

Eligibility Criteria

Inclusion Criteria

  • history of mild-moderate traumatic brain injury
  • impaired attention or concentration
  • >1 year since traumatic brain injury
  • ability to participate in neurofeedback and mindfulness meditation
  • daily access to a smart phone
  • on stable dosage of neuropsychological medications with no significant changes planned for the duration of the study
  • no prior history of a meditation practice

Exclusion Criteria

  • severe mental illness or psychological symptoms (severe depression, suicidality, disabling anxiety, PTSD, psychosis, dissociation)
  • significant pre-morbid learning disability
  • current or recent (in past year) history of significant drug or alcohol abuse
  • medical illness severe enough to result in an attentional disorder
  • neurodegenerative disease
  • non-fluency in English.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02615535). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search